Matinas BioPharma Holdings, Inc. Share Price
MTNBMatinas BioPharma Holdings, Inc. Stock Performance
Open $1.76 | Prev. Close $1.71 | Circuit Range N/A |
Day Range $1.76 - $1.76 | Year Range $0.47 - $4.25 | Volume 300 |
Average Traded $1.76 |
Matinas BioPharma Holdings, Inc. Share Price Chart
About Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Matinas BioPharma Holdings, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
17-Sep-25 | $1.76 | $1.76 | +0.00% |
17-Sep-25 | $1.76 | $1.76 | +3.53% |
16-Sep-25 | $1.70 | $1.70 | -4.49% |
15-Sep-25 | $1.78 | $1.78 | +0.00% |
11-Sep-25 | $1.76 | $1.78 | +5.33% |
04-Sep-25 | $1.75 | $1.69 | -6.63% |
03-Sep-25 | $1.90 | $1.81 | +0.00% |
FAQs on Matinas BioPharma Holdings, Inc. Share Price
Can I buy Matinas BioPharma Holdings, Inc. shares in India?
What is the share price of Matinas BioPharma Holdings, Inc.?
What is the 5 year returns of Matinas BioPharma Holdings, Inc.?
What are the high & low stock price of Matinas BioPharma Holdings, Inc. today?
What is the 52-week high and low of Matinas BioPharma Holdings, Inc. stock?